Connect with us

Private Companies

ATAI Launches Discovery Program for Next-Gen Mental Health Treatments

The article ATAI Launches Discovery Program for Next-Gen Mental Health Treatments was originally published on Microdose.

atai Life Sciences Launches Invyxis…

Published

on

The article ATAI Launches Discovery Program for Next-Gen Mental Health Treatments was originally published on Microdose.

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

January 27, 2022 06:59 ET | Source: atai Life Sciences

Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs)

Early focus will be on designing unique, novel compounds aimed at the serotonin 5-HT2A receptor with other central nervous system (CNS) targets to follow

This new platform company is a further step-up in atai’s commitment to next-generation treatments, complementing its machine learning-powered computational chemistry with EntheogeniX and biosynthesis-based drug discovery approaches with TryptageniX

NEW YORK and BERLIN, Jan. 27, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today launched Invyxis, a new, wholly owned platform company committed to developing new chemical entities (NCEs) and to further pioneering next-generation mental health treatments. Invyxis will bring proven medicinal chemistry tools and comprehensive biological screening approaches to atai’s growing enterprise of drug discovery and design.

The launch of Invyxis is a further step-up in atai’s growth and commitment to innovation in the treatment of mental health disorders. The new atai platform company has entered into a strategic collaboration with Dalriada Drug Discovery, specialists in the discovery of small molecule therapeutics. Invyxis will harness a broad array of methods including structure-based design, synthetic chemistry, high-throughput screening, and in vivo characterization.

Invyxis’ goal will be to discover new agents with potential in treating mental health disorders, generating NCEs to progress into atai’s research & development pipeline of psychedelic and non-psychedelic compounds. The platform company will initially focus on agonists at the 5-HT2A receptor, recognizing the importance of this key serotonin receptor system in treating a range of mental health disorders.

Expanding intellectual property (IP) has been essential to atai’s strategy since inception, with key investments made to unlock NCEs. In 2019, atai launched EntheogeniX to pursue novel compounds using machine learning-based drug discovery, and the recent launch of TryptageniX added biosynthetic capabilities to atai’s discovery efforts.1,2 atai has already made substantial progress in its drug discovery efforts to date, synthesizing and screening approximately 300 compounds and identifying novel scaffolds that display potential in targeting mental health disorders.

“The global mental health crisis continues to escalate at an alarming rate and many patients do not find sufficient relief from currently available treatments. We urgently need newer, better options and innovative drug discovery is integral to this,” said Florian Brand, Chief Executive Officer and Co-Founder of atai Life Sciences. “With the addition of Invyxis, atai is now even more equipped to bring forward revolutionary new treatments and optimize next-generation therapies to better meet patient needs.”

“Expanding IP and growing our library of NCEs has been essential to our strategy since our inception,” said Srinivas Rao, Chief Scientific Officer and Co-Founder of atai Life Sciences. “By establishing differentiated potential treatments, with near, middle, and long-term developmental timelines, we add value and sustainability to our extensive pipeline of novel compounds with potential in targeting mental health indications. We are uniquely positioned, as a leading developer of psychedelic therapeutics, with the resources necessary to commit to and deliver this forward-looking strategy.”

“The use of psychedelic compounds to create improved next-generation mental health therapies is a highly promising and emerging field,” said Diana Kraskouskaya, Dalriada Chief Executive and Co-Founder. “We’re delighted to be partnering with atai to make an impact in this area. This creation of Invyxis brings together Dalriada’s ability to provide a rapid set-up and advancement of NCE discovery pipelines and atai’s expertise in the preclinical and clinical development of psychedelic therapeutics.”

Mental health disorders impact over 1 billion people around the world, representing a growing global crisis, but medical innovation has failed to offer recent novel solutions.3 Only 7 treatments have been approved by the FDA for psychiatry disorders since 2015; a time in which approximately 100 have been advanced in oncology.4 atai Life Sciences is proud to be a driving force in mental health innovation and to make Invyxis the latest addition to its diversified platform, to develop new therapeutic options in key areas of patient unmet need.

References:

  1. ATAI Life Sciences and Cyclica Launch Joint Venture to Revolutionize Drug Development for Mental Health Disorders. [Press Release] https://www.businesswire.com/news/home/20191111005299/en/ATAI-Life-Sciences-and-Cyclica-Launch-Joint-Venture-to-Revolutionize-Drug-Development-for-Mental-Health-Disorders. Published November 11, 2019. Accessed January 18, 2022.
  2. atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai’s supply chain. [Press release] https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-launches-tryptagenix-further-expand-atais. Published December 9, 2021. Accessed January 18, 2022.
  3. Rehm J, Shield KD. Global Burden of Disease and the Impact of Mental and Addictive Disorders. Curr Psychiatry Rep. 2019;21(2):10.
  4. U.S. Food and Drug Administration. New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products. Accessed January 5, 2022. https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

atai’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.

atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. atai has offices in New York, London, and Berlin. For more information, please visit www.atai.life.

Contact Information

Media Contact:

Camilla Dormer

VP, Communications

Email: camilla@atai.life

Investor Contact:

Chad Messer

VP, Investor Relations

Email: chad@atai.life

Read More

Trending